Lupin Limited has informed the Exchange about an update on acquisition of VISUfarma B.V., the Netherlands.
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.4 pts more than Nifty Midcap 150 and 0.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Lupin Limited has informed exchanges that its wholly owned Dutch subsidiary Nanomi B.V. is still in the process of acquiring the entire share capital of VISUfarma B.V., an Amsterdam-based company. The deal was originally expected to close by end of calendar year 2025, but the company now expects completion by February 28, 2026, pending certain closing conditions. This is a status update, not a change in the deal itself. The original definitive agreement was signed on September 29, 2025.
The deal is progressing but is delayed by roughly two months from the original timeline. For shareholders, this is a minor near-term uncertainty, but the acquisition is still on track and no terms appear to have changed. The delay is likely to be seen as a small negative for sentiment in the short term.